Replay available

CT Private Equity Trust (LSE:CTPE) — Investor Presentation

Investor Presentation hosted by CT Private Equity Trust (LSE:CTPE) on Investor Meet Company, held 2023-03-31.

Fri, March 31, 2023 at 9:00 AMendedReplay
CT Private Equity Trust (LSE:CTPE) — Investor Presentation
Company
CT Private Equity Trust PLC (LSE:CTPE)
Date
Fri, Mar 31, 2023, 9:00 AM ET
Replay
Watch the replay on this page · 56 min

On 6ix: 6ix.com/event/ct-private-equity-trust-plc-ctpe-investor-presentation-2

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Good afternoon, and welcome to the CT PRIVATE EQUITY TRUST PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Just click q and a, scroll to the bottom, type your question, and press send. Company may not be in a position to answer every question received during the meeting itself. However, the company review all questions submitted today and publish responses where appropriate to do so. Before we begin, we'd like to submit the following poll. I'd now like to hand you over to Peter Brown, Investment Trust sales. Good afternoon. Thank you, and, good afternoon, everyone. It's my pleasure to, represent, Columbus Red Needle. I am part of the Investment Trust sales team. And Hamish Mayer is with me, who is the lead manager on the CT PRIVATE EQUITY TRUST, and he will be running through his presentation, which will cover the last financial year up to December 22.

0:52 As mentioned, if you've got any questions, please put them in the chat room, and we'll come to them towards the end of the presentation, which should be in about thirty, thirty five minutes. So with that, I'll pass to Hamish, and all over to you, Hamish. Thanks, Peter. Good afternoon, everybody. Thank you very much for joining this presentation. I'm going to update you on the results for our company for 2022 and one or two of the events that have taken place since then.

1:21 I'm just gonna go through these slides, and we'll... Should have plenty of time for q and a afterwards. So just to summarize, we had a a good year in, 2022. We've just, come out with our results out of this week. The NAV total return for the year was, plus 14.8%. And, you know, that that comes after a number of good years already, so we're, delighted to able to sustain our strong performance. Couple of, things of note, during the year, we had a strong number for realizations, a £125,000,000. It's slightly down on last year, but last year was an exceptional year where there were 161,000,000 of realizations.

2:14 But to some extent, there was a catch up from 2020 where, for obvious reasons, there wasn't so much going on. But a 125,000,000 is an excellent number. We have announced our latest quarterly dividend at six point seven nine pence. It'll be paid at the end at the end of April. We've got a dividend yield of around 6% at the moment. One of the, striking things that happened, during the year was that we sold our holding in the Italian funeral homes company, San Siro, and made an excellent return of nearly nine times our money and a 90% IRR. And, three quarters of that came through in cash, a quarter of it was reinvested back into the new deal.

3:01 Co investments now account for 43% of the portfolio. It's been fairly constant throughout the year. Our long term aim is to move towards 50% in co investments with about the same in funds. So having a balance between co investments and funds, which we think is optimal in terms of the risk profile of the company with enough concentration on individual companies that if they go well, they can substantially move the needle. If they don't work out, it's not the end of the world, and we get some natural, very extensive diversification through our funds portfolio. There were a couple of new investments made at the tail end of 2022, and I'll talk more about these in a moment. It was Family First, which is a chain of nursery...

3:54 Nurseries in the South Of England, and MedSpa, which is a chain of essentially medical spa is providing aesthetic treatments in, Canada. Looking at the long term progression of value, this chart, the dark blue is the NAV. The light blue are the cumulative dividends. You can see we've had pretty good growth in in recent years. And, just to remind everyone, the dividend is calculated, each quarter, and it's 1% of the average of the last four quarters NAV. And if that calculation leads to a number that is below the previous dividend, we maintain the previous dividend. So it's a... If you like, an upwards only dividend policy.

4:44 We've had this in place for over a decade now, and, the, annual dividend growth comes out at 16.2% per annum, which is pretty respectable. And as I mentioned earlier, the next dividend is paid at the end of this month. In terms of the, NAV and share price total return, the share price is the light blue line, the NAV total return, the dark blue one. You can see the long term. There's a very close relationship between these. But in the short term, there has been a divergence because the discount has opened out. Share price is a bit below where it was when we prepared this presentation, but it has it has been recovering. Still a very sort of an obvious anomaly between the the share price and the NAV growth, and we're hoping that that anomaly can be be rectified in the near future.

5:43 If we go on to the next page, it's just another way of looking at performance over one, three, and five years and looking at the discrete numbers for each of the individual years. And you can see that we've had a good 2022 followed by an excellent '21 and '20, and, you know, good growth before that as well. So, you know, private equity is a a long term asset class. You should judge it over the long term, and the long term numbers are very, are very strong. In terms of outstanding commitments, these are commitments to private equity funds, and people like to monitor this just to make sure that we're not, getting carried away in terms of, committing money that we don't have at, to our disposal. But we are, we've got quite modest outstanding commitments at the moment, 179,000,000, which is, very comfortable compared to our historic range. And, it is necessary to have, a decent amount of outstanding commitments because these commitments are drawn down and the portfolio is refreshed. And if we didn't have outstanding commitments, we'd run a risk of not being able to fully reflect... Refresh the portfolio from year to year.

7:00 In terms of debt, we don't have much debt, a small amount of net debt at the year end, and it's gone up slightly since then. We do believe in the benefits of gearing because we expect to make returns from investments that are far in excess of the cost of borrowing, and that therefore enhances the return to shareholders. We also don't believe in running with large piles of cash on the balance sheet because that detracts from the return, to shareholders. We have a large revolving credit facility. It's about a £115,000,000, roughly. Most of that is available, should we need it for making new investments. If we have a mismatch between realizations and new investments, then we can use that borrowing facility, and we have done effectively over the years.

7:53 This page just runs through the new investments that have been made during 2022. There are lots of different ones, a mixture of fund commitments and co investments. They are diverse by the sectors that they're covering, the geographies, and the the managers that are involved. Common factor is that they're largely mid market buyout funds or or growth equity funds in the mid market, mainly in Europe with a small number in North America. And that has continued on. Here we see a number of the new ones, which I'm gonna talk about in a minute. We've also made some new investments during 2023.

8:42 There's three new ones here, GT Medical, which basically as a sort of novel form of treatment for cancer, LeadVenture, which is a software company in The US, and Acxiom, which is a new lower mid market fund, a so called emerging manager fund, where we've identified some very able young people that were... That we're backing in this new fund. So I've got some slides on some of the more recent co investments, which I will talk about quickly. There's a bit more detail on these slides that you can consult at your leisure. But the first one is Leader ninety six. So this is an electric bike company.

9:33 It's based in Bulgaria, and it services markets largely in Western Europe. So Germany, France, Spain, The UK. There is quite low penetration of ebikes as they're called into The UK and in France and Spain. It's far commoner in, Germany and The Netherlands, but the trend is well established. And this is a a good way of playing the trend towards people, using these electric bikes. The deal is led by the Rohattan Group whom we've invested with a few times over the years, and we'd aim to make about four times our money over the next four or five years. Next investment is Refine. So Refine is a company that does audits for good manufacturing practice for pharmaceutical companies.

10:27 This used to be a bit of a cottage industry, the sort of small consultancies, but it's now becoming larger in scale and refine are growing quite rapidly into a strongly growing market. The market itself is growing because lots of new drugs are coming onto the market. And, the the companies that make these drugs, they all need to have these GMP audits. And they, the beauty of the refined approach is that when they have an audit done for one client, that data can be used for other clients. So it, it makes the situation a bit more efficient for the, for the customers. And, you know, therefore, it's growing quite strongly. So we're hoping to make a good strong return here. It's not an expensive deal. We've come in at less than eight times money... Eight eight times EBITDA rather, and we'd expect to make probably nearly four times our money over the next four years.

11:23 Another new investment is one two three Dentist. This is a chain of, dental practices in Canada. Deal is led by Peloton, who are one of the, Canadian mid market players. And this is a really reasonably straightforward rollout of, dental practices across Canada. They basically buy them and then aggregate them, and they reap the benefits of scale from buying synergies and and that sort of thing. And the people that are doing this buildup have done a very similar thing already, so there's a relatively low risk from a management point of view. Another new investment is Neurolens. Now Neurolens is a deal led by MVM. Now MVM specialize in health care oriented investments.

12:11 And what Neurolens does is it has a system which consists of hardware and software, which is used to diagnose and treat something called digital, vision syndrome. So that is basically something you get if you spend a lot of time looking at screens or suddenly a proportion of the population get it, and it's quite painful. It can be debilitating, and this allows, allows it to be corrected. This is sold to opticians and optometrists, and, you know, there's a lot of, growth potential here. MVM specialize in identifying companies that have got good proven technology, but where the product has not been marketed very well. And this is... This falls into that category, and, and they improve the business. And we should make a good return from this over the next four years or so.

13:07 Next one is MedSpa. So this is the chain of of spas, in, Canada and The US. Basically, people have various treatments that they have treatments on their skin and Botox and things like that, which is a strong growth market. It's quite a resilient market. And once people start using a MedSpa or going to MedSpa, they tend to continue to go. It's something that, you know, has proven to be quite resilient right the way through, you know, the ups ups and downs of the economic cycle. And so this is about building out a chain across North America. And it's led by Persistence Capital. That's a Toronto based firm that we've known for a number of years.

13:59 Family first is the chain of nurseries that I mentioned earlier. It's 96 nurseries, mainly in the South Of England around London and Southeast, some of them in the West Midlands. It's a kind of upmarket nursery. And, you know, the demographic demographics are very supportive of ongoing growth for this sector and for this company. And August Equity have experience in this area. I mean, they've actually been in this company for about three years already, and then they've brought us into it. So we're very much investing into a known entity here with a known, lead manager. There've been quite a lot of realizations, as I mentioned earlier, in 2022. This is a full list of them. I'm not gonna talk about them all individually, but you can see that they come from a very wide range of different types of company, different geographies, different, private equity houses.

14:56 And the outcomes on the right hand side of this slide are are very good. You know, you're getting, many times your money. In most case... You know, almost every case, you're making a good profit. As a rule of thumb, if the money multiple is north of about two and a half times and the IRR, the internal rate of return is is above 25 for a percent or so, that's a good outcome. So most of these would rank as as good outcomes, and it's... You know, it continues on over the page. A lot of these businesses have a kind of technology angle or a health care angle, and there's no surprise there. That's an area where private equity has shown an appetite, you know, both at the mid market scale and at the larger end of the private equity market. So these are businesses that generally got good secular growth operating in growing markets, the businesses themselves are well positioned within these strongly growing markets.

15:57 And that is... That trend has continued into 2023. We've had number of realizations so far. We haven't even finished the first quarter or finishing today. In terms of drawdowns, the portfolio is being refreshed all the time. So lots of new investments going in. So we've talked about the co investment investments already, but there are also others that are being drawn down by the funds. Again, well diversified by sector, geography, and the lead manager.

16:31 These... This is really laying the foundations for future growth in NAV. Again, you can see quite a strong technology and health care

16:44 bias, if you like, here. Again, this is where the, private equity market is most most interested just now. And that's continued on into, 2023 as well. This shows you the pattern of drawdowns and distributions over the long term. Now when you have lots of distributions, you also tend to have quite a lot of drawdowns. It's reinvesting the same money. So there's clearly a relationship between these two numbers. If you don't have much in the way of exits, you're probably not gonna have so much in the way of new investments. So, you know, there's generally a a matching. We try and reinvest the the proceeds of of realizations, as I said, to build growth in asset value for the future.

17:38 Looking at our largest underlying holdings, just say a word or two about some of these. These are things to sort of watch out for as we go through the year. Sigma is a electrical components company. Now this is a US based business. It's quite... It's in quite well. We may exit this later this year or potentially early next year, but we're not gonna be in it for a lot longer, and we should make a perfectly good return. The next three investments, CoreTracks, ASTED, and TWMA are all led by Buckthorn who specialize in the energy markets... Energy services markets. Ashtead is now actually a listed company, and we're we're selling down that. And that's made quite a good return, which improves by the day because the the share price is well above the IPO price. It went to the AIM market in November 2021.

18:29 It's it's it's basically doubled since then. CoreTrax is is doing quite well. It's a play on activity in the oil and gas sector, particularly decommissioning. So there's an element of center... Counter cyclicality about it. And then TWMA also involved in oil and gas, but what it does is cleans up oil rig cuttings, cleans them, and

18:58 to avoid polluting the environment and also to lower the cost of production. And that has been a bit behind plan. It was... Suffered a bit during COVID, but they've now got some really strong contracts coming through in The UAE. And so we think this investment is gonna be fine.

19:19 Aurora is a a payments company in The US, which is is going well. It's a fairly new deal, but it's making good progress. Jollies is a... The second largest pet shop chain in Britain, which has also done well in recent years. Some of you probably rushed out and bought a dog for yourselves during COVID. If so, you're... You've got that in common with about half the British population. And, obviously, the pet shops would like to stay open all the way through COVID, so, this business has done really quite well. San Siro is the funeral home company I mentioned that, we have largely exited, but this is the the rump, position if you like, which is still quite substantial.

20:05 And we'd expect to make, you know, probably at least two times our money on this rump, over the next, next few years. ATEC is a small insurance company. That's a deal led by Kester Capital. They're trying to sell this at the moment. ATEC provides insurance for caravans and little, boats. So it's a niche, a niche insurer, which is is done well. Accuvein is the the vein visualization company. I've talked about this before. It basically allows doctors and nurses to visualize veins on people's arms and and legs more easily and can put in a needle, and align much more effectively. That was held up a bit during COVID because the salesman couldn't actually go into the hospitals and sell the product.

20:56 That's now recovering quite strongly. And then our tenth largest position is Weirdfish, the clothing company. So this has been a bit of a volatile ride for us in the last couple of years. It did... At the beginning of COVID, it looks as though it was in serious trouble, then it did really well as everybody shifted to online purchasing. And then since everybody has come back to work, etcetera, there's less ecommerce going on, and ecommerce is actually good for businesses like this. They make higher margins, so profits have been under pressure a bit. We did try and sell this business late, well, early last year, but the buyer, after quite a lot of diligence, dropped out and then trading deteriorated.

21:41 So we're going to be in this for a bit longer, but I think we will do alright in the end. In terms of some of the statistics on our co investment portfolio, which as I mentioned, accounts for about 43% of the value of the company. This is our holdings of private companies directly. So these underlying businesses have done well. I mean, they've had, on average, 36% revenue growth during 2022. The size of the companies, you can see there, you know, average revenue about 64, the median about 40. So these are these are not huge companies, but they're certainly not the corner shop. You know, these are substantial businesses with several tens of millions of pounds of of revenue.

22:27 And in terms of EBITDA, earnings before interest, tax, depreciation, amortization, or in other words, cash flow. The growth there has been very healthy, 22%, and the average, EBITDA is about, just under £14,000,000. Median's a bit lower than that, but you can see the the, you know, the size of of the average company. Obviously, there's been a little bit of margin contraction as you can see there, but the profit's not growing as rapidly as revenue. Why is that? Well, it's to do with all the pressures that we read about into the inflation, higher energy prices, higher other input prices, supply chain disruption, and shortages have led to some margin diminution, but you're still getting very healthy growth here, which does very much underpin the overall growth in NAV.

23:28 In terms of the number of underlying holdings, now we we have actually about nearly 500 underlying holdings in this company. It has actually gone up slightly during the year. We've invested in a 118 new deals, you know, either through co investments or through the funds that we are invested in. There were 60 exits, and some information on the exits. So the... There was a average uplift of 36% above the most recent carrying value for the exits. So three months prior to exit, on average, these businesses were valued at 2.9 times money, and they were sold out at four times money. So there's a nice boost there. When we look at the weighted average, so, skew... You know, adjusting for the different size of the companies, the uplift is even greater. It's about 70% uplift, which is very punchy.

24:27 About 14% of the companies exited during the year, which is quite quite a reasonable number. The the uplifts actually compare well with the previous year, so the uplifts are actually slightly higher in 2021 compared to 2022, which itself was a pretty good year. So the point about this is that you look at our share price, it sits at a big discount to asset value, and people are thinking, well, is the asset value correct? Well, on the evidence of the exits, it clearly is... You know, it is at the very least a fair valuation. You could actually argue that the valuation is is quite conservative given that when assets are sold, they're sold at a very significant premium to the latest carrying value. Now that is what you would expect to happen, but it certainly doesn't provide any justification for our shares being at a very large discount to NAV.

25:32 Looking at, you know, who's been buying the companies that we've been selling, well, 44 went to trade, so that's being sold to other companies in the same sector. 52% went to other private equity firms, so typically larger private equity firms.

25:49 Hardly any went to the stock market. Nothing that represents one company, actually, and 1%... Or two percent one company was bought by its own management. Now that split between trade sale and private equity sponsor is a... Is roughly constant. That's that's what we would expect, roughly half and half. IPOs are a rare route for exits, and they were even rarer in 2022 than they they usually are. '21, there was quite a lot of IPOs, but, you know, I think the most... The busiest quarter might have accounted for some of the 16% of exits. Typically, it would be well below 10%.

26:34 There's not a major exit route for our portfolio. And, you know, where were the exits achieved?

26:40 Well, the largest individual component reflects the largest portion of the portfolio, and it was in The UK. Italy is obviously strongly represented here because of the San Siro exit, and The Netherlands was actually the stacks exit, which was the clean room consumables that we sold earlier in the year.

27:00 So, you know, pretty healthy environment for exits during 2022. In terms of the geography, we're 42% in The UK. Most of the rest is in Continental Europe. There's about 17% in The States. That's the largest private equity market in the world. So you'd expect that. And in terms of vintage, about 60% is more than three years old, 50% more than four years old. Why do I mention that? Well, we're typically looking at a four year hold for an investment. So as they come into the three to four year age bracket, these are... These deals are maturing. And so it's from that maturing element that you will get realizations.

27:49 And realizations, as we've discussed, tends to drive NAV growth. And so we will always have a steady flow of realizations because we've always got an element to the portfolio that is maturing. In terms of the valuation, it's actually gone down slightly, an EV to EBITDA ratio of 11.6 times, slightly down from last year. And that compares with an entry price of about 8.7. You know, typically, we're in the eights, you know, to eight point something, which is pretty good value for mid market, high growth companies. And in terms of the underlying indebtedness of these companies, that is is not high at all. It's 3.1 times on a debt to EBITDA, which is, very similar to what it was last year.

28:40 So these businesses are, in general, not very highly geared. In terms of sectors, we've got the breakdown here. Two large sectors are information technology and health care, which between them account for nearly half the portfolio. And, you know, I've mentioned this already. There's some good secular growth characteristics in both these these sectors, you know, software and services. A lot of this has to do with the digitalization of the economy, which is... Was accelerated during the the pandemic. And then in health care, you know, the demographic arguments and are are, you know, well known to most people. There are also some significant technological advances, which mean that this sector is generally growing faster than the economy as a whole, and there's some very innovative companies involved in the different tiers of the health care sector, and, you know, we're exposed to quite a few of them.

29:38 Business services is also quite significant. Consumer discretionary is not a large sector for us, but we are involved in it. You know, it's a large part of the economies that we invest in. So if that's... It'd be natural that we'd have some exposure there.

29:56 So, basically, just to conclude and give a few comments on the outlook, portfolio has done very well. It's proved to be resilient right the way through the pandemic and out the other side. It's also proved to be resilient under the current sort of macroeconomic challenges. Interest rates have gone up. Inflation's gone up, but we still continue to make good returns. And we've still got plenty of firepower for new investments. Obviously, we'll reinvest the money that comes back from the exits, but we've also got a large revolving credit facility that's available as well. We are finding plenty of new investments in terms of co investments and funds. We have no shortage of opportunities to invest.

30:41 And if anything, pricing is improving. We can find good value in the lower mid market. As I mentioned, exits have held up extremely well. Good premium to previous carrying value, which, you know, suggests our our valuations are very sound. And, you know, the underlying portfolio, as I mentioned, has has grown well in terms of revenue and profits. There's plenty of appetite for private equity globally. You know, that is likely to continue for the foreseeable future. There's lots of people who have increased their allocations in recent years, and they're not going to reverse reverse that in any sort of meaningful way. The commitments are out there. They would be gradually drawn down. They'll go into the market.

31:31 You know, they will vary the rate of deployment of capital depending on how they're feeling and how, you know, risky they think things are, but the longer term picture is that that money will be be deployed. And as I mentioned, information technology and health care is a significant area for us and a good driver of long term growth.

31:51 So as we just finished the first quarter of twenty twenty three, we are are confident that we will continue to build value for shareholders over the medium and longer term, and we'll have a better idea of that as we progress further into the year. So think I would now like

32:14 to answer some questions. So, Hamish, thank you very much indeed for the presentation. Ladies and gentlemen, do please continue to submit your questions using the Q and A tab situated in the right hand corner of the screen. But just while the team take a few moments to review those questions submitted already today, I'd like to remind you the recording of the presentation, along with a copy of the slides and the published Q and A can be accessed via your investor dashboard. As you can see, we have received a number of questions throughout today's presentation. Thank you to everyone for submitting those. Peter, can I just ask you to read those questions out where appropriate to do so for Hamish to give his response? Yes. Sure. Thank you, Hamish, that update. We've had a few questions. We'll start with the the first and probably the most common, which is obviously very important for shareholders, and that is basically the share price or, in fact, the discount to the net asset value.

33:02 Been a few questions. I'll come to them in a minute. I mean, I think what what is great is that the near 15% gain in the NAV is slightly different to most other asset classes, and we've seen the share price drop over the last six to nine months to the discount. But the questions specifically are, is there any action to try and reduce that discount? Is there any way that we can reduce the discount close to NAV, either through buybacks, or any thoughts you've got to try and narrow that discount.

33:32 And, basically, I think just a side point, it might be the fact that the market is valuing the shares on the back of... Or not having confidence in the valuations in not just this portfolio, but other portfolios that are trading on big discounts. Can you run through a little bit about the valuation control and and that kind of thing, basically? Absolutely. I mean, obviously, the shares trading at a significant discount to NAV, you know, it's 30 something percent at the moment, is is frustrating for me as is for all of you. I mean, essentially, what happens in the stock market is that when they go into a sort of risk off mode, they tend to sell shares in private equity investment trusts rather indiscriminately.

34:20 And, you know, our discount is slightly narrower than our direct peers, but it's still still sort of unacceptably large in in my view. The converse is also true that when the market is feeling more optimistic and it goes into a sort of risk on mode, you'll tend to see those discounts narrow very significantly, and that can happen quite quickly. And, you know, at some point during the year, that is highly likely to happen when people start seeing through, you know, the current sort of challenges in the macroeconomic situation and look at the other side, and they can see, you know, plenty of growth. And they start to sort of realize, well, actually, this portfolio has been growing strongly in NAV, and it's delivering strong growth in dividends. So that's real money that's being handed back.

35:10 You know, the the only sort of long term solution for discounts is for for me to find more buyers of the, of the shares and sellers. So most of our, shareholders are wealth managers. You know, we have got some pension funds and other institutions, but a lot of them are wealth managers, and there's also the platforms, and there's our savings plan. And we think this is an excellent long term investment, so we're constantly trying to convince people to to buy the shares. I mean, at the moment, when you're on a very big discount, I mean, it is a great opportunity. Now, people will ask about discount control mechanisms. So when the discount is this wide, you know, there is a limit to what can be done directly there. We have done buybacks in the past. We do that very sparingly because although that does provide a bit of an enhancement to NAV, it does shrink the size of the company.

36:09 And if you were to do too much of that, you basically make the investment itself

36:15 riskier than it was because you still got substantial outstanding commitments. So if you do buybacks, you shrink the NAV, but you still got the commitments. Yes. You will enhance the NEV per share a little bit. To make a big difference, you'd have to buy back quite a lot. And once that money has gone, that's it. It's gone. You can't use it for investments. So we always have to balance the potential use of money for buybacks against what we can do with that money in new investments. And when you buy a new investment, you might be targeting sort of 25, 30, 35% per annum return. That is not just a one off, once return. That's a return every year for probably four or five years.

37:03 Whereas if you buy back the shares, your your enhancement is instantaneous, but that's it. It's only once. It doesn't compound itself, year after year. So, that doesn't mean we're never gonna do buybacks, but it does mean that there is quite a high, sort of threshold before we would actively consider that. And, you know, we are constantly getting advice from our stockbrokers about what isn't isn't a good time to be contemplating buybacks. But when they recommend to us that by sort of clearing a loose line of stock, we would significantly improve the share price, then we will do that. But that that is quite a rare situation.

37:43 So I think, you know, the best policy is really to tell everybody about the shares, point out the the value, explain to them what's going on in the underlying portfolios, the dynamics of that portfolio. And, you know, we should see the shares going better. I mean, since the results came out a couple of days ago, the the price has improved significantly, and I'd expect it to continue to improve from here.

38:12 Okay. That's that's fine. Thank you very much for that insight. On a slightly different tack, someone's asked a little bit more detail on weird fish and I know you mentioned it briefly in your presentation. Could you give another minute on each Yeah. Regarding your thoughts? Yeah. So has this this equipment that, as I mentioned, it helps people identify sort of veins and arteries. It uses an infrared technology to shine on the on the patient's arm or leg.

38:43 It's sold largely in The US. It's sold into hospitals. You have to convince the the clinical people to use it. Now when the salesman can demonstrate it to to those clinical people, they tend to they tend to buy. They were held back significantly during COVID because for months on end, they weren't allowed to go into the hospitals and demonstrate their equipment. So there's an element of catch up now taking place.

39:13 So, you know, that that that investment should be fine. It's led by MVM whom I mentioned earlier. They specialize in investing into companies which have got technology or products that work, but where it requires a bit more sort of commercial input to maximize the potential of those products and hence the profits of the business. And that's exactly what they're doing. So, you know, that will be fine. WeirdFish has been a bit sort of grand old duke of York, you know, goes up to the top of the hill and comes down again.

39:48 The people that run it are very experienced, you know, clothing industry executives. They're very much incentivized to do a good job for us, and they have been buffeted around by the, you know, the volatile environment we've had for the last few years, but they will recover again. In a way, their ecommerce offering went from being relatively unsophisticated at the beginning of COVID to being really quite slick a few months later and drove profits that has decreased in significance, but the actual efficient system they have got is still there. Obviously, anything that's consumer related at the moment in The UK has been under pressure.

40:37 You just need to walk along your local high street to see that. But, you know, that should recover later in the year. So, you know, we're still making good money on this on this deal. It's just a question of how much we're gonna make when we eventually exit it. The exit is probably realistically another couple of years out. It might be quicker than that. We nearly sold it at the beginning of last year. There was a very large, well known clothing chain that was about to buy it. And what happened there was that there was a change in management in that company, and they dropped the idea of doing the acquisition. And that's quite understandable. A new person comes in. They're not necessarily gonna follow through with a sort of three quarters executed plan of the previous management. So that was... I think we were probably a bit unlucky on that on that side.

41:33 And then since then, the the businesses softened off a bit, well, quite a bit, actually. But I think we will be okay on this one in the long term. Okay. Thank you for that. Moving on to investments that you've got in the portfolio, how precise are the expected return figures, and how often are they... How do they vary in in in the future when they actually come about? Yeah. Well, I mean, the interesting thing about investment management, including private equity investment management, is it's all about predicting the future. And, you know, that is a kind of uncertain business.

42:11 You know, if it was easy, you know, I wouldn't still be doing this. So the the the numbers we have in the presentation, these are our target returns. If you like, these are the sort of base case returns. And it doesn't always work out like that, which I don't think you'll be surprised to hear. But most of the time, it does work out at or close to those numbers.

42:38 I always think if you're an investment manager, if you're if you're right or broadly right, 65% of the time, you're probably gonna be in a very good position. And and we probably do... We probably have that kind of a hit rate, probably better than that. Occasionally, things will go badly wrong, and you'll lose everything, but that is rare. I mean, that does happen. It has happened to me a few times in the last sort of thirty years. And I think any seasoned private equity investor would admit that they have lost money or, in fact, lost everything on some investments. And if they say they haven't, it probably means that they're... You know, they haven't had much experience or they're probably being a bit economical with the truth. So most of the time, we get it right.

43:25 And if we can do 25% net IRR for a co investment, you know, two and a half times plus, we will be doing fine. Our long term track record for our co investments we've done of... In this portfolio, we've done over 80 since twenty o three. Long term return, I think, is about 2.3 times money with an IRR, I think, about 23%. It's actually in our results statement, which is only just below our target of 25%. So I think we can probably say that we do hit our target or get very close to it.

44:12 Lovely. With regards to realizations, you mentioned it in the in the presentation, and many of the realizations are to other private equity firms. The question comes, are... Is there a vested interest in maintaining valuations at these levels and that valuations may not be supported by public markets. Or more broadly, why do you think that there's very few that go to an IPO rather than a resale? Yeah. I mean, most of them don't go to IPO because they... You know, they're probably not big enough at the point of exit. I mean, the the the viable minimum size for a new issue as we used to call them is now, you know, it's in the sort of hundreds of of of millions rather than, you know, 50,000,000 or 80,000,000, which it used to be.

45:02 And so a lot of our businesses aren't actually that big when they're when they're sold, when they when they actually exit. Secondly, private equity has, in the last couple of decades, has, if you like, filled

45:17 the space that used to be occupied by the junior sections of the stock market. You know, some of you remember the USM and, obviously, AIM exists, but it's not quite as comprehensive as the main list. And then there's the smaller end of the of the the the official list or the main list as as they call it. And,

45:41 you know, a lot of companies would go public, and then they would discover that there was no liquidity in their shares, and they were not able to to use the public markets to raise capital. They'd struggled to do rights issues or to... Or placings, and yet they would have all the disadvantages of being a public company. And also management would find it harder to make money. You know, they they would not typically have a large proportion of the shares. And so a lot of people who would other... In a... In another age have been running public companies are now running private equity backed, companies. So the companies are staying private for longer. So that's one of the reasons that IPOs are are, you know, a very small proportion of our exits.

46:33 What was the first part of the question? Well, you've answered it, basically. It was about... Well, we... We'll move on to next question, but it's basically about valuations in in public markets. Is there... Do we have a vested in... Does private equity have a vested interest? Yes. Keeping the valuations up, you know, so it's a sort of pass the parcel exercise. Well, the larger private equity funds have got people who are backing these funds in order to make returns. You know, they have to make absolute returns. It's not a relative game at all. You know, the the people that are buying these companies, they, you know, they won't get their carried interest if they don't make adequate returns. So they're very hard headed people. I mean, they will not actually buy companies unless they're sure they can make a return. So just because it's sold from one

47:25 private... Smaller private equity firm to a larger private equity firm doesn't imply that, you know, somebody is overpaying. You might as well say that if you had shares in BP and you sell them to somebody else, that the next person has got no chance of making money. Well, you know, BP or any large public company, CLX, Smith, Klein, whatever, they have been growing probably for a hundred years and continue to grow. So it's just about, you know, people,

47:55 you know, doing part of the journey, if you like, and then somebody else taking the the later part of the journey and then... And the business continue to grow. Also, different investors have different required rates of return. Different, private equity houses will put in different capital structures. You know, some of them will have more debt, some will have smaller amounts of debt that has a direct bearing on the returns that they can make. So, you know, just because you're selling it to another private equity firm doesn't mean that, you know, that they can't make money. I mean, they they can probably also make money. I mean, they may overpay for it. From our point of view, if we're selling and somebody overpays for it, well, that's, you know, that's their their their problem really rather than ours.

48:44 But as I say, you know, people, they don't deal on a whim. They they deal after months and months of scrutiny and work. So they, you know, they they they tend to, you know, have a very solid basis for the the price that they're paying. Okay. Lovely. And moving on, but still on the same vein of valuations, how do you reconcile the EV... EBIT or the PE multiple compression witnessed in The UK listed small company space? We're receiving some NAVs and... The open ended funds and some share prices down 20 to 40% Yeah. With the NAV performance of the trust. In other words, the the holdings you've got seem to have held up, whereas the others seem to be compressed a bit. Yeah. Because our portfolio isn't a sort of proxy for this, the, you know, the small cap index.

49:33 It, you know, doesn't have the same sort of... It doesn't have the same sectoral balance. You've got to bear in mind that private equity companies are, by definition, a small subset of all the available companies, including the public companies that are out there. And so, you know, they are not, you know, they're not uninfluenced by what's going on in the stock market and the wider economy, but they're not, you know, they're not a sort of proxy for it. So,

50:04 you know, you... There's a temptation for people to read across from small cap listed companies to private equity and try and come up with, you know, complicated models that will try and identify value. I think that's a pretty inexact science. So inexact is almost not worth doing.

50:26 So the other thing is that a lot of these smaller listed companies, their prices ran up far higher than anything that happened in in private equity. And therefore, when the correction came, they probably came rattling down. I mean, the public markets, as I'm sure most of you are aware, have a tendency to sort of overbuy things and then oversell things. Private equity, because it's, you know, it's valued every quarter, tends to have, you know, smaller amplitude waves if you like. So, you know, I think I think if you look at the EV to EBITDA multiples of private equity portfolios like ours and compare them with the public markets, you'll find they're actually pretty competitive. Most of the time, they're lower, actually.

51:15 And it's another illustration of the value that is there. Do you know the average EBITDA of the portfolio and revenue growth, yeah, on top of your head? For the public companies. I don't attach. Otherwise, I'd probably just mentioned it. Okay. But for these companies, it's obviously, you know, it's a point of thing. The current valuation and EBITDA growth is, you know, is the last year of 22%, which I think will compare well with

51:43 with... You... You've gotta be careful because, you know, you can't compare EBITDA growth directly with earnings growth. How to do different things that was connected, but not exactly the same thing. And, you know, you've got to make sure that you are comparing, you know, apples and apples rather than apples and oranges. Sure. I think we'll we'll finish. We'll answer your questions after the presentation, and we will get around to you if I haven't mentioned one of your questions. But we'll finish on the fact that 2023, we've probably seen some realization volumes reduced because of the volatility we've seen in markets. Is that true? And do you have much visibility for the rest of the year? Was it too early to tell? Yeah. So things things are still being sold.

52:30 So, you know, certainly, things have not fallen off a cliff or anything like that. It's... You know, visibility... It's difficult at this stage of the year to have a lot of visibility. I mean, last year, as I said, we did a 125,000,000 of exits. You know, if we did a 100,000,000 this year, I think that would be a pretty good outcome.

52:52 It's too early to tell, whether that would happen. In 2020, when we had a very depressed year, we still had about 40,000,000 or 39,000,000 of of exits. So that would be a sort of lower... Very much a lower bounding figure. So, you know, a 100,000,000 would be would be a good outcome for this year. It could be better than that. You know, throughout most of 2022, I didn't expect we get up to anything like a 125,000,000,

53:26 notwithstanding the fact that I knew that San Siro was likely to exit for, you know, about half the year. So, you know, I tend to be... I tend to on the side of caution when I'm talking about numbers here. So, hopefully, we'll get a decent number for 2023.

53:46 That's fantastic. Thank you very much indeed for covering off so many questions today. As Peter said, we'll we'll pick up on any of those other questions. And we're appropriate to do so. The team will publish response in the investor meet company platform. Hamish, just before we redirect investors to provide you their feedback, I know it's particularly important to yourself and Peter. Can I just ask you just for a few final closing comments, please? Yeah. Well, thanks very much everybody for listening this afternoon.

54:10 You know, our our company has been going now for, you know, twenty four years. We've delivered excellent growth over that time period. If you if you compare progress in this company with what could have been achieved in the stock market, we've delivered an annualized return that's approximately double the annualized return that you would get in the stock market. We've had capital gains that are three or four times the amount that you would have achieved in the stock market. That's because private equity does carry higher risk. But if it's done properly, you are paid for that risk, you will get a premium return. And I think the results that we've just delivered in addition to those we've done in previous years do actually prove that if you take that moderate risk, with us, then you will be rewarded.

54:57 So thanks very much indeed for your support. We will continue to manage the company to try and grow the NAV further this year and for many years to come. Thank you.

55:08 That's fantastic. Hey, Mitch. Peter, thanks indeed for updating investors today. Can I please ask investors not to close the session? It should be automatically redirected to provide your feedback in order the team can better understand your views and expectations. This will only take a few moments to complete, and it's greatly valued by the team. On behalf of the management team of CT PRIVATE EQUITY TRUST PLC, we'd like to thank you for attending today's presentation. That concludes today's session. Thank you, and good afternoon.

Follow CT Private Equity Trust PLC into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Hamish Mair

Fund Manager at CT PRIVATE EQUITY TRUST PLC

Peter Brown

Investment Trust Sales Manager at CT PRIVATE EQUITY TRUST PLC

More from CT Private Equity Trust PLC